Sernova

06/24/2026

Did you know, beta cells are responsible for producing insulin, the hormone that helps regulate blood glucose levels? In people living with ( ), these insulin-producing cells are destroyed by the immune system.​

With our Cell Pouch bio-hybrid organ, we aim to support the long-term survival and function of therapeutic cells to help reduce the burden of T1D. Learn more about our approach: https://sernova.com/our-focus/type-1-diabetes/

06/21/2026

Whether it’s helping manage daily routines, offering encouragement, or simply being a steady source of support, fathers play an important role in helping children living with ( ) navigate each day. ​

This , we’re recognizing and celebrating all of the dads and father figures whose care and support make a meaningful difference.

06/19/2026

Last week at the , our team connected with key opinion leaders, industry peers, and members of the diabetes community for discussions about innovation in ( ) research.​

As part of these important conversations about the needs of people living with T1D, we highlighted our advancement of the Cell Pouch bio-hybrid organ and its potential to provide a functional cure for T1D.​

Thank you to all for a great conference!​

Learn more about us:

Meet the team committed to advancing durable solutions for patients living with chronic disease.

06/17/2026

We’re thrilled to announce that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for our autologous islet transplantation for the prevention of diabetes due to pancreatectomy, a procedure often leading to the development of Type 3c diabetes ( ).

T3cD is a secondary form of often resulting from a pancreatectomy for patients with chronic pancreatitis or damage to the pancreas. This designation underscores the potential of our program to address a critical gap in care for people living with T3cD.

Read more in our press release: https://bit.ly/3Sdmgu5

05/29/2026

Attending the American Diabetes Association’s upcoming ? We will be there to connect with industry leaders and experts across the diabetes community about the latest advancements in the field and our work to develop our Cell Pouch bio-hybrid organ in combination with therapeutic cells. Reach out to connect! ​

For more info on our work, visit our website: https://sernova.com/

05/20/2026

This , we are recognizing the unique ways impacts women differently.​

Hormonal changes can affect blood glucose levels and increase variability. These differences highlight the need for more personalized, adaptable treatments, reflecting our mission to develop an approach designed for all people living with .​

Learn more: https://bit.ly/4bs4Ui0

05/14/2026

We are pleased to share a new article published in Drug Delivery Leader by members of our team. The article explores the evolving landscape of cell therapy delivery platforms and the importance of creating a biologically supportive implantation environment to ensure durable therapeutic outcomes.

Read the article for insights on efforts to advance novel therapeutic approaches that have the potential to improve outcomes for people living with ( ): https://bit.ly/4wzbXAk

05/10/2026

Mothers carry so much love, strength, and resilience - often all at once. For moms supporting children living with , that role comes with an added layer of vigilance, advocacy, and unwavering care.​

This , we’re honoring the dedication and courage of every who shows up, every single day, with strength and love.​

Join us in celebrating and honoring the moms who do it all and then some! 💐

04/29/2026

Our Cell Pouch Bio-hybrid Organ offers the potential to be a transformational treatment solution for people with ( ) by reducing or eliminating the need for life-long insulin injections. ​

Learn more about our clinical data by reviewing the latest corporate presentation on our website: https://sernova.com/investors/

04/15/2026

Did you know ( ) is rising fastest among minority youths in the U.S, with these communities often facing barriers in access to care and diabetes technology?​

Differences in access to education, specialists, and tools like insulin pumps and continuous glucose monitors can greatly impact outcomes for people living with . ​

This , we’re highlighting the need for equitable access to diabetes education, screening, and treatment technology. At Sernova, we’re committed to helping bridge these gaps and support solutions that improve care and allow access for all communities.​

Learn more: https://bit.ly/4m7KC3n